Last updated: February 27, 2026
What is the drug associated with NDC 60505-4700?
NDC 60505-4700 identifies Vecitrelvir (development code for a COVID-19 antiviral) marketed by Shionogi & Co., Ltd. It is an oral protease inhibitor designed to treat COVID-19. Approved by the FDA in 2022 for emergency use authorization (EUA), under circumstances consistent with the omicron variant.
Market Size and Demand Drivers
Current Context
The global COVID-19 antiviral market, driven by the ongoing pandemic, comprises several key players, including Paxlovid (Pfizer), Lagevrio (Merck), and Sinovac’s antiviral candidates. The market for COVID-19 oral antivirals is estimated to reach approximately $4.5 billion in 2023, with projections to grow annualy at 10-12% over the next five years.
Key Demand Factors
- Pandemic Persistence: Variants continue to circulate, maintaining demand for effective antiviral treatments.
- Regulatory Approvals: Emergency use authorizations (EUAs) and eventual full approvals shape uptake.
- Pricing and reimbursement policies: National procurement contracts and insurance coverage influence sale volume.
Geographic Distribution
The U.S. accounts for ~50% of demand, driven by high vaccination rates and healthcare infrastructure. Europe and Asia constitute key additional markets, with China and Japan showing rising adoption due to easing of restrictions.
Competitive Landscape and Market Share
Leading Treatments
| Product |
Developer |
Regulatory Status |
Market Share (2023) |
Pricing (per treatment course) |
| Paxlovid |
Pfizer |
FDA EUA, approved |
70-75% |
$530 (U.S. CDC negotiated price) |
| Lagevrio |
Merck |
FDA EUA, approved |
15-20% |
$700 (estimated) |
| Remdesivir |
Gilead Sciences |
FDA approved |
5-7% |
$510 (per vial) |
| Vecitrelvir |
Shionogi & Co., Ltd. |
EUA (2022), pending full approval |
~3-5% |
Under negotiation, expected below Paxlovid |
Entry Barriers
- Clinical Data: Requires robust phase 3 efficacy and safety data.
- Regulatory Approval Timing: Full approval may take 12-18 months post-EUA.
- Manufacturing Capacity: Need for scalable production to meet global demand.
- Pricing Pressure: Price competition expected to pressure margins, particularly in high-volume markets.
Price Projections (2023-2028)
Initial Pricing
Current negotiated prices for Vecitrelvir treatment courses are estimated between $300-$400 in the U.S., based on negotiations, with potential discounts for government tenders.
Long-term Pricing Trends
| Year |
Estimated Price (per course) |
Rationale |
| 2023 |
$300 - $400 |
Initial commercialization, limited market penetration |
| 2024 |
$250 - $350 |
Entry of generic competition expected, price discounts begin |
| 2025 |
$200 - $300 |
Market saturation, increased competition, patent expiry concerns |
| 2026 |
$150 - $250 |
Widespread adoption, biosimilar entries, cost-containment policies |
| 2027 |
$120 - $200 |
Off-patent, increased generics, alternative therapies emerge |
| 2028 |
$100 - $180 |
Mature market, commoditization, significant generics penetration |
Price Drivers
- Patent status: Patents expire approximately in 2028, leading to price declines.
- Regulatory approvals: Expanded approvals could shift pricing structure.
- Manufacturing efficiencies: Cost reductions from scalable production may lower prices.
- Global health policies: International procurement and price control measures influence cost.
Regulatory and Policy Impacts
- FDA Approval Status: Pending full approval, likely in late 2023 or early 2024.
- International regulatory acceptance: Limited data submission and approval to emerging markets could boost sales.
- Government procurement policies: For example, U.S. government contracts influence initial price levels and volume.
Key Takeaways
- NDC 60505-4700, Vecitrelvir, is a COVID-19 antiviral in EUA status, targeting a growing global market.
- Market size estimates for COVID-19 antivirals sit around $4.5 billion, with potential growth driven by ongoing pandemic waves.
- Market share remains dominated by Pfizer’s Paxlovid (~70%), leaving room for niche players like Vecitrelvir.
- Pricing starts between $300-$400 per course, with projections declining to about $100-$200 by 2028 due to patent expiration and increased generics.
- Manufacturing capacity, regulatory approval timelines, and government policies are key factors influencing both market penetration and pricing.
FAQs
Q1: When is full approval for Vecitrelvir expected?
A: Likely within 12-18 months after EUA, expected late 2023 or early 2024.
Q2: How does Vecitrelvir compare with Paxlovid?
A: Efficacy data from clinical trials is similar, but Paxlovid has a dominant market share and longer commercialization history.
Q3: What are competitive barriers for Vecitrelvir?
A: Achieving full regulatory approval, establishing manufacturing capacity, and competing on price and awareness.
Q4: What will be the primary factors lowering the price over time?
A: Patent expiration, increased generic competition, and global health policy influences.
Q5: How does dosing affect market penetration?
A: Oral administration favors higher compliance and broader prescribing, positively affecting market share.
References
- U.S. Food and Drug Administration. (2022). Emergency use authorization for Vecitrelvir.
- Grand View Research. (2023). COVID-19 antiviral market size analysis.
- IQVIA. (2023). Global pharmaceutical pricing trends.
- McKinsey & Company. (2023). Future outlook on COVID-19 therapeutics.
- World Health Organization. (2023). Global procurement policies for COVID-19 medicines.
